Alphatec Holdings, Inc. (NASDAQ: ATEC) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.72 | Insider Own | - | Shs Outstand | 153.79M | Perf Week | 16.29% |
| Market Cap | 1.58B | Forward P/E | 16.86 | EPS next Y | 0.61 | Insider Trans | 0.30% | Shs Float | 121.05M | Perf Month | 7.87% |
| Enterprise Value | 2.06B | PEG | - | EPS next Q | 0.11 | Inst Own | - | Short Float | 11.29% | Perf Quarter | 24.76% |
| Income | -111.00M | P/S | 1.94 | EPS this Y | 145.37% | Inst Trans | - | Short Ratio | 5.46 | Perf Half Y | -18.15% |
| Sales | 816.00M | P/B | - | EPS next Y | 86.61% | ROA | -13.91% | Short Interest | 13.67M | Perf YTD | -51.14% |
| Book/sh | -0.08 | P/C | 13.29 | EPS next 5Y | 48.53% | ROE | -818.99% | 52W High | 23.29 -55.86% | Perf Year | -31.60% |
| Cash/sh | 0.77 | P/FCF | - | EPS past 3/5Y | - | ROIC | -7.24% | 52W Low | 6.82 50.73% | Perf 3Y | -26.20% |
| Dividend Est. | - | EV/EBITDA | 158.46 | Sales past 3/5Y | 29.60% 39.43% | Gross Margin | 66.15% | Volatility | 6.26% 4.76% | Perf 5Y | -28.86% |
| Dividend TTM | - | EV/Sales | 2.52 | EPS Y/Y TTM | 36.28% | Oper. Margin | -5.55% | ATR (14) | 0.50 | Perf 10Y | 145.93% |
| Dividend Ex-Date | - | Quick Ratio | 1.07 | Sales Y/Y TTM | 33.33% | Profit Margin | -13.50% | RSI (14) | 58.37 | Recom | 2.20 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.89 | EPS Q/Q | - | SMA20 | 6.96% | Beta | 0.77 | Target Price | 16.22 |
| Payout | 0.00% | Debt/Eq | 17.22 | Sales Q/Q | 15.05% | SMA50 | 9.33% | Rel Volume | 1.10 | Prev Close | 10.50 |
| Employees | 913 | LT Debt/Eq | 15.25 | Earnings | Oct 29 | SMA200 | -15.16% | Avg Volume | 2.52M | Price | 10.28 |
| IPO Date | Jun 01, 2006 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.78% 1.07% | Net Debt/EBITDA | 36.07 | Volume | 2,756,346 | Change | -2.10% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-05-26 | Reiterated | BMO Capital | Outperform | $11 → $12 |
| Aug-05-26 | Reiterated | UBS | Buy | $15 → $16 |
| Jul-28-26 | Initiated | UBS | Buy | $15 |
| Jul-23-26 | Initiated | Stephens | Overweight | $15 |
| Jul-08-26 | Initiated | BMO Capital | Outperform | $11 |
| Jul-08-26 | Reiterated | Stifel Nicolaus | $20 → $13 | |
| May-06-26 | Reiterated | Lake Street | Buy | $25 → $15 |
| May-06-26 | Reiterated | Piper Sandler | Overweight | $25 → $14 |
| May-06-26 | Reiterated | Needham | Buy | $23 → $14 |
| May-06-26 | Reiterated | Canaccord Genuity | Buy | $25 → $23 |
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/30/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 816 | 764 | 612 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 276 | 232 | 187 | — | — | — | — | — | — | |
| Gross Profit | 538 | 532 | 424 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 508 | 499 | 450 | — | — | — | — | — | — | |
| Research and Development | 78 | 76 | 81 | — | — | — | — | — | — | |
| Other Operating Expense | -2 | 39 | 29 | — | — | — | — | — | — | |
| Operating Income | -45 | -82 | -136 | — | — | — | — | — | — | |
| Interest Expense | 41 | 21 | 25 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -24 | -40 | -1 | — | — | — | — | — | — | |
| Net Income Before Taxes | -111 | -143 | -162 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -111 | -143 | -162 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -111 | -143 | -162 | — | — | — | — | — | — | |
| Net Income | -111 | -143 | -162 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.72 | -0.96 | -1.13 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.72 | -0.96 | -1.13 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.72 | -0.96 | -1.13 | — | — | — | — | — | — | |
| EBITDA | 13 | -40 | -54 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.95 | 4.13 | 2.15 | — | — | — | — | — | — | |
| Gross Margin | 65.93 | 69.63 | 69.28 | — | — | — | — | — | — | |
| Operating Margin | -5.51 | -10.73 | -22.22 | — | — | — | — | — | — | |
| Net Margin | -13.60 | -18.72 | -26.47 | — | — | — | — | — | — | |
| Shares Outstanding | 155 | 150 | 143 | — | — | — | — | — | — | |
| Market Capitalization | 1,593 | 3,156 | 1,313 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Miles Patrick | CEO | Sep 10 '26 | Buy | 8.81 | 115,000 | 1,013,150 | 5,893,551 | Sep 10 |
| Marshall Tyson Eliot | GENERAL COUNSEL & CORP. SEC. | Aug 05 '26 | Sale | 9.65 | 8,168 | 78,821 | 630,398 | Aug 07 |
| MCGINNIS KAREN K | Director | Jun 11 '26 | Sale | 8.01 | 6,050 | 48,461 | 94,671 | Jun 12 |
| Valentine Keith | Director | May 11 '26 | Buy | 7.00 | 35,000 | 245,000 | 232,271 | May 11 |
| Valentine Keith | Director | May 08 '26 | Buy | 7.54 | 43,847 | 330,606 | 197,271 | May 11 |
| Valentine Keith | Director | May 07 '26 | Buy | 7.49 | 56,153 | 420,586 | 153,424 | May 11 |
| Marshall Tyson Eliot | GENERAL COUNSEL & CORP. SEC. | Apr 07 '26 | Option Exercise | 2.52 | 102,500 | 258,050 | 661,959 | Apr 09 |
| Koning John Todd | CHIEF FINANCIAL OFFICER | Mar 13 '26 | Sale | 12.36 | 79,789 | 986,192 | 600,721 | Mar 17 |
| Lish Scott | CHIEF OPERATING OFFICER | Mar 13 '26 | Sale | 12.30 | 260,535 | 3,204,581 | 815,704 | Mar 17 |
| Sponsel David | EVP, SALES | Mar 11 '26 | Sale | 12.52 | 163,452 | 2,046,419 | 504,932 | Mar 13 |
| Hunsaker Craig E | EVP, PEOPLE & CULTURE | Mar 09 '26 | Sale | 12.45 | 82,765 | 1,030,424 | 1,726,209 | Mar 10 |
| Hunsaker Craig E | EVP, PEOPLE & CULTURE | Mar 06 '26 | Sale | 12.22 | 33,602 | 410,616 | 1,808,974 | Mar 10 |
| Marshall Tyson Eliot | GENERAL COUNSEL & CORP. SEC. | Mar 05 '26 | Sale | 12.49 | 88,835 | 1,109,549 | 559,459 | Mar 09 |
| Hunsaker Craig E | EVP, PEOPLE & CULTURE | Feb 12 '26 | Option Exercise | 2.14 | 251,176 | 538,501 | 1,424,201 | Feb 17 |
| Sponsel David | EVP, SALES | Feb 05 '26 | Sale | 13.79 | 60,425 | 833,261 | 349,500 | Feb 06 |